Disease Modifying Drugs for Multiple Sclerosis – Overview of Drug Information Service (DIS) Presentation

The primary document used for this review was prepared by the Oregon Evidence Based Practice Center. The drug class review on disease modifying drugs for multiple sclerosis was completed in July 2007. The document includes comparative efficacy and safety data for the following as single agents: glatiramer acetate, interferon beta-1a for intramuscular injection, interferon beta-1a for subcutaneous injection, interferon beta-1b, mitoxantrone, and natalizumab. For these agents, the review assessed all available dosage forms. The review focuses specifically on efficacy and safety in patients with multiple sclerosis.

Several manufacturers submitted supplemental information for our review, including:

- Bayer, the manufacturer of interferon beta-1b (Betaseron),
- EMD Serono/Pfizer the manufacturers of interferon beta-1a (Rebif), and
- Biogen Idec the manufacturer of interferon beta-1a (Avonex) and Natalizumab (Tysabri).

The DIS reviewed the document as well as the supplemental information submitted to us. We concluded the efficacy and safety data for the included agents is current and complete. Although the Oregon monograph did not include the PROOF trial, the results of this trial do not change the review's conclusions.

The P&T Committee requested supplemental information on the following topic relative to the disease modifying drugs for multiple sclerosis:

- List of specific agents currently marketed in the US, along with information about indications for use, dosing and administration, dosage forms available, generic availability, storage and stability, dose adjustments in special populations, and black box warnings. The DIS will prepare an overview of this information and present it at the November P&T meeting.

October 30, 2008.